Search
InflaRx NV
IFRXAdd to Watchlist
2.240USD
-0.090-3.86%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
161.94MMarket Cap
LossP/E TTM
More Details of InflaRx NV Company
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Info
Ticker SymbolIFRX
Company nameInflaRx NV
IPO dateNov 08, 2017
CEORiedemann (Niels C)
Number of employees74
Security typeOrdinary Share
Fiscal year-endNov 08
AddressWinzerlaer Str. 2
CityJENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code07745
Phone493641508180
Websitehttps://www.inflarx.de/
Ticker SymbolIFRX
IPO dateNov 08, 2017
CEORiedemann (Niels C)
Company Executives of InflaRx NV
Name
Name/Position
Position
Shareholding
Change
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of InflaRx NV?
The top five shareholders of InflaRx NV are: Mr. Nicolas Fulpius
How many institutions hold shares of InflaRx NV (IFRX)?
As of 2026Q1, 82 institutions hold shares of InflaRx NV, with a combined market value of approximately 19.59M, accounting for 13.30% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4596250.00.